NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly NYSE:LLY edged higher on Thursday after the drugmaker announced a deal with Atai Life Sciences, a partnership that may generate up to $1 billion in milestone payments.
- Eli Lilly ended the session at $1,169.17, rising 1.08%. U.S. regular trading was already finished.
- AtaiBeckley NASDAQ:ATAI closed at $7.15, up 33.3%.
- Lilly will make an upfront payment of $2.8 billion. An additional $1 billion may be paid if certain milestones are achieved.
Eli Lilly NYSE:LLY rose on Thursday after it agreed to acquire AtaiBeckley NASDAQ:ATAI, in a potential $3.8 billion psychedelic-drug transaction. Shares of Lilly climbed 1.08%, while the S&P 500 slipped 0.51%.
Atai shares closed at $7.15, putting them just $0.40 above Eli Lilly’s $6.75-per-share cash offer.
The spread represents 16% of the potential $2.50 contingent value right. This straightforward calculation does not account for time value or risks related to deal closure. Nonetheless, it indicates that investors are significantly marking down the chance of receiving the full milestone payment.
Lilly will make an upfront payment of around $2.8 billion, with an additional $1 billion tied to milestones. The table below sizes up those obligations against Lilly’s existing operations.
| Comparison | Value |
|---|---|
| Cash to be paid at closing | $6.75 per share; around $2.8 billion |
| Potential further payment | $2.50 per share; roughly $1 billion |
| Straightforward implied additional value | $0.40 per share; 16% of the highest possible amount |
| First-quarter Mounjaro and Zepbound sales | $12.8 billion; 4.6 times the initial payment |
| Estimated market value increase for Lilly on Thursday | $11.2 billion; 3.0 times the top possible deal value |
The majority of the contingent value is tied to VLS-01, the second-leading candidate. Of the possible $2.50 payout, $2 hinges on the initiation or approval of its Phase 3 trial. Just $0.50 relies on the approval and DEA rescheduling of BPL-003.
BPL-003 has entered Phase 3 trials targeting treatment-resistant depression. Jefferies analyst Andrew Tsai projects potential sales between $1 billion and $2 billion upon successful completion. Early data is anticipated in early 2029.
Barclays analyst Emily Field noted that the acquisition “offers upside potential in large markets like depression.” Lilly reported that Phase 2b clinic visits typically lasted around two hours, with benefits extending for months. Reuters
The commercial impact of treatment burden may be significant. Johnson & Johnson’s NYSE:JNJ Spravato can necessitate clinic visits as often as twice a week. Last year, AbbVie NYSE:ABBV acquired another psychedelic depression drug for as much as $1.2 billion.
Scale additionally eased balance-sheet worries. Lilly’s shares rose on Thursday, increasing its market value by about $11.2 billion—close to triple the top purchase price.
The rise extended beyond just deals. The health-care and life-sciences index gained 0.31%. Despite Thursday’s rebound, it could not offset the week’s earlier losses. Lilly was still trading 1.6% under its July 10 value and 5.4% beneath its record closing price from July 7.
Lilly has no scheduled events listed on its investor calendar for next week, with its second-quarter earnings call set for August 5. Investors are expected to monitor Atai’s deal spread along with any SEC merger filings.
Risks persist. Clinical, FDA, and DEA challenges affect both programs. Regulatory or shareholder hold-ups could prevent the deal from closing in the third quarter. The contingent right could result in no payout.
Lilly shareholders continue to face limited fixed exposure when compared to present sales. Atai’s most recent closing price maintains a steep discount on potential scientific breakthroughs.
Related articles: NYSE:LLY
